Rationale for treating cancer with somatostatin analogs.
Minuto
F
F
Department of Endocrinology and Metabolism, University of Genoa, Genoa, Italy. minuto@unige.it
Ferone
D
D
Arvigo
M
M
Barreca
A
A
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D002453:Cell Cycle / Q000187:drug effects; D006801:Humans; D008938:Mitosis / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017481:Receptors, Somatostatin / Q000145:classification / Q000187:drug effects / Q000378:metabolism*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D017481:Receptors, Somatostatin; D013004:Somatostatin